Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.

Strand V, Mysler E, Moots RJ, Wallenstein GV, DeMasi R, Gruben D, Soma K, Iikuni N, Smolen JS, Fleischmann R.

RMD Open. 2019 Oct 1;5(2):e001040. doi: 10.1136/rmdopen-2019-001040. eCollection 2019.

2.

A novel treatment in the management of genital ulceration in Behçet's disease.

Benson RM, Kirwan J, Moots RJ.

Clin Exp Rheumatol. 2019 Oct 2. [Epub ahead of print] No abstract available.

PMID:
31577218
3.

Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis.

Zhao SS, Yoshida K, Jones GT, Hughes DM, Duffield SJ, Tedeschi SK, Lyu H, Moots RJ, Solomon DH, Goodson NJ.

Arthritis Res Ther. 2019 Jul 22;21(1):177. doi: 10.1186/s13075-019-1958-z.

4.

Comorbidity burden in axial spondyloarthritis: a cluster analysis.

Zhao SS, Radner H, Siebert S, Duffield SJ, Thong D, Hughes DM, Moots RJ, Solomon DH, Goodson NJ.

Rheumatology (Oxford). 2019 Oct 1;58(10):1746-1754. doi: 10.1093/rheumatology/kez119.

PMID:
31220322
5.

Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States.

Zhao SS, Ermann J, Xu C, Lyu H, Tedeschi SK, Liao KP, Yoshida K, Moots RJ, Goodson NJ, Solomon DH.

Rheumatology (Oxford). 2019 Nov 1;58(11):2025-2030. doi: 10.1093/rheumatology/kez171.

PMID:
31081033
6.

Biosimilars in the Americas: the future by consensus.

Moots RJ.

Clin Rheumatol. 2019 May;38(5):1497-1499. doi: 10.1007/s10067-019-04549-7. Epub 2019 Apr 23. No abstract available.

PMID:
31016576
7.

Smoking does not protect patients with axial spondyloarthritis from attacks of uveitis.

Zhao SS, Macfarlane GJ, Jones GT, Gaffney K, Hughes DM, Moots RJ, Goodson NJ.

Ann Rheum Dis. 2019 Sep;78(9):1287-1288. doi: 10.1136/annrheumdis-2019-215348. Epub 2019 Apr 20. No abstract available.

PMID:
31005901
8.

Caught in a Trap? Proteomic Analysis of Neutrophil Extracellular Traps in Rheumatoid Arthritis and Systemic Lupus Erythematosus.

Chapman EA, Lyon M, Simpson D, Mason D, Beynon RJ, Moots RJ, Wright HL.

Front Immunol. 2019 Mar 11;10:423. doi: 10.3389/fimmu.2019.00423. eCollection 2019.

9.

Human neutrophils activated via TLR8 promote Th17 polarization through IL-23.

Tamassia N, Arruda-Silva F, Wright HL, Moots RJ, Gardiman E, Bianchetto-Aguilera F, Gasperini S, Capone M, Maggi L, Annunziato F, Edwards SW, Cassatella MA.

J Leukoc Biol. 2019 Jun;105(6):1155-1165. doi: 10.1002/JLB.MA0818-308R. Epub 2019 Feb 28.

PMID:
30817049
10.

The impact of smoking on response to TNF inhibitors in axial spondyloarthritis: methodological considerations for longitudinal observational studies.

Zhao S, Yoshida K, Jones GT, Hughes DM, Tedeschi SK, Lyu H, Moots RJ, Solomon DH, Goodson NJ.

Arthritis Care Res (Hoboken). 2019 Feb 14. doi: 10.1002/acr.23851. [Epub ahead of print]

PMID:
30762311
11.

Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR Biologics Register for Ankylosing Spondylitis (BSRBR-AS).

Zhao S, Jones GT, Macfarlane GJ, Hughes DM, Dean LE, Moots RJ, Goodson NJ.

Rheumatology (Oxford). 2019 May 1;58(5):811-819. doi: 10.1093/rheumatology/key371.

PMID:
30561738
12.

Measuring disease activity and response to treatment in rheumatoid arthritis.

Buzatu C, Moots RJ.

Expert Rev Clin Immunol. 2019 Feb;15(2):135-145. doi: 10.1080/1744666X.2019.1559050. Epub 2018 Dec 20.

PMID:
30556738
13.

Rituximab in neurological disease: principles, evidence and practice.

Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots RJ, Kim HJ, Robertson NP, Cree BAC, Jacob A.

Pract Neurol. 2019 Feb;19(1):5-20. doi: 10.1136/practneurol-2018-001899. Epub 2018 Nov 29. Review.

PMID:
30498056
14.

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.

Chadwick L, Zhao S, Mysler E, Moots RJ.

Curr Rheumatol Rep. 2018 Nov 9;20(12):84. doi: 10.1007/s11926-018-0799-0. Review.

15.

Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations.

Ozguler Y, Leccese P, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Çelik AF, Fortune F, Gaudric J, Gul A, Kötter I, Mahr A, Moots RJ, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, Hatemi G.

Rheumatology (Oxford). 2018 Dec 1;57(12):2200-2212. doi: 10.1093/rheumatology/key242.

PMID:
30107448
16.

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.

Zhao S, Chadwick L, Mysler E, Moots RJ.

Curr Rheumatol Rep. 2018 Aug 9;20(10):57. doi: 10.1007/s11926-018-0769-6. Review.

17.

Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome.

Leccese P, Ozguler Y, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gül A, Kötter I, Mahr A, Moots RJ, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, Hatemi G.

Semin Arthritis Rheum. 2019 Feb;48(4):752-762. doi: 10.1016/j.semarthrit.2018.05.008. Epub 2018 May 19.

PMID:
29954598
18.

Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.

Moots RJ, Curiale C, Petersel D, Rolland C, Jones H, Mysler E.

BioDrugs. 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4. Review.

PMID:
29790131
19.

Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H, Govoni M, Vastesaeger N.

Clin Rheumatol. 2018 Jul;37(7):2017-2018. doi: 10.1007/s10067-018-4131-1.

PMID:
29752584
20.

Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H, Govoni M, Vastesaeger N.

Clin Rheumatol. 2018 May;37(5):1417-1420. doi: 10.1007/s10067-018-4074-6. Epub 2018 Apr 2. Erratum in: Clin Rheumatol. 2018 May 12;:.

PMID:
29611083
21.

Etanercept for the treatment of rheumatoid arthritis.

Zhao S, Mysler E, Moots RJ.

Immunotherapy. 2018 Mar 1;10(6):433-445. doi: 10.2217/imt-2017-0155. Epub 2018 Feb 27. Review.

PMID:
29482402
22.

Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy.

Fisher BA, Everett CC, Rout J, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, Carr A, Pease CT, Price EJ, Sutcliffe N, Makdissi J, Tappuni AR, Gendi NST, Hall FC, Ruddock SP, Fernandez C, Hulme CT, Davies KA, Edwards CJ, Lanyon PC, Moots RJ, Roussou E, Richards A, Sharples LD, Bombardieri M, Bowman SJ.

Ann Rheum Dis. 2018 Mar;77(3):412-416. doi: 10.1136/annrheumdis-2017-212268. Epub 2017 Dec 23.

23.

Biosimilars: From Extrapolation into Off Label Use.

Zhao S, Nair JR, Moots RJ.

Curr Pharm Des. 2017;23(44):6746-6751. doi: 10.2174/1381612824666171129193258. Review.

PMID:
29189127
24.

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.

Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators.

Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16.

PMID:
28629665
25.

Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.

Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B.

PLoS One. 2017 Jun 5;12(6):e0179308. doi: 10.1371/journal.pone.0179308. eCollection 2017.

26.

Fibromyalgia in Behçet's disease: a narrative review.

Jobanputra C, Richey RH, Nair J, Moots RJ, Goebel A.

Br J Pain. 2017 May;11(2):97-101. doi: 10.1177/2049463717701393. Epub 2017 Mar 22.

27.

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.

Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B.

PLoS One. 2017 Apr 27;12(4):e0175207. doi: 10.1371/journal.pone.0175207. eCollection 2017. Erratum in: PLoS One. 2017 Jun 5;12 (6):e0179308.

28.
29.

The Behçet's centres of excellence.

Moots RJ, Fortune F, Situnayake D.

Rheumatology (Oxford). 2018 Apr 1;57(4):594-595. doi: 10.1093/rheumatology/kex037. No abstract available.

PMID:
28340170
30.

Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.

Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, Pease CT, Price EJ, Sutcliffe N, Gendi NST, Hall FC, Ruddock SP, Fernandez C, Reynolds C, Hulme CT, Davies KA, Edwards CJ, Lanyon PC, Moots RJ, Roussou E, Giles IP, Sharples LD, Bombardieri M.

Arthritis Rheumatol. 2017 Jul;69(7):1440-1450. doi: 10.1002/art.40093. Epub 2017 Jun 5.

31.

Complementary and Alternative Medicine Use in Rheumatoid Arthritis: Considerations for the Pharmacological Management of Elderly Patients.

Zhao S, Otieno F, Akpan A, Moots RJ.

Drugs Aging. 2017 Apr;34(4):255-264. doi: 10.1007/s40266-017-0443-0. Review.

PMID:
28224284
32.

Behcet's disease.

Nair JR, Moots RJ.

Clin Med (Lond). 2017 Feb;17(1):71-77. doi: 10.7861/clinmedicine.17-1-71.

33.

Building a rheumatology team for East Africa: A call for action!

Genga EK, Moots RJ, Oyoo OG, Otieno FO.

Rheumatology (Oxford). 2017 Sep 1;56(9):1441-1442. doi: 10.1093/rheumatology/kew432. No abstract available.

PMID:
28031440
34.

Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome.

Ng WF, Miller A, Bowman SJ, Price EJ, Kitas GD, Pease C, Emery P, Lanyon P, Hunter J, Gupta M, Giles I, Isenberg D, McLaren J, Regan M, Cooper A, Young-Min SA, McHugh N, Vadivelu S, Moots RJ, Coady D, MacKay K, Dasgupta B, Sutcliffe N, Bombardieri M, Pitzalis C, Griffiths B, Mitchell S, Miyamoto ST, Trenell M; UK Primary Sjögren’s Syndrome Registry.

Rheumatol Int. 2017 Apr;37(4):623-631. doi: 10.1007/s00296-016-3637-6. Epub 2016 Dec 24.

35.

Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.

Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, Donaldson F, Dimonaco S, Rubbert-Roth A, van Vollenhoven R, Genovese MC.

Rheumatology (Oxford). 2017 Apr 1;56(4):541-549. doi: 10.1093/rheumatology/kew370. Review.

36.

Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy.

Bezzina OM, Gallagher P, Mitchell S, Bowman SJ, Griffiths B, Hindmarsh V, Hargreaves B, Price EJ, Pease CT, Emery P, Lanyon P, Bombardieri M, Sutcliffe N, Pitzalis C, Hunter J, Gupta M, McLaren J, Cooper AM, Regan M, Giles IP, Isenberg DA, Saravanan V, Coady D, Dasgupta B, McHugh NJ, Young-Min SA, Moots RJ, Gendi N, Akil M, MacKay K, Ng WF, Robinson LJ; UK Primary Sjögren's Syndrome Registry.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1714-1723. doi: 10.1002/acr.23165. Epub 2017 Oct 9.

37.

Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis.

Zhao S, Challoner B, Khattak M, Moots RJ, Goodson NJ.

Rheumatol Int. 2017 Feb;37(2):239-244. doi: 10.1007/s00296-016-3590-4. Epub 2016 Nov 4.

38.

Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis.

Wright HL, Cox T, Moots RJ, Edwards SW.

J Leukoc Biol. 2017 Mar;101(3):785-795. doi: 10.1189/jlb.5A0616-258R. Epub 2016 Oct 12.

PMID:
27733572
39.

Low-density granulocytes: functionally distinct, immature neutrophils in rheumatoid arthritis with altered properties and defective TNF signalling.

Wright HL, Makki FA, Moots RJ, Edwards SW.

J Leukoc Biol. 2017 Feb;101(2):599-611. doi: 10.1189/jlb.5A0116-022R. Epub 2016 Sep 6.

PMID:
27601627
40.

Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe.

Holden SE, Currie CJ, Lennon M, Reynolds AV, Moots RJ.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):679-84. Epub 2016 May 9.

PMID:
27191345
41.

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.

Vastesaeger N, Kutzbach AG, Amital H, Pavelka K, Lazaro MA, Moots RJ, Wollenhaupt J, Zerbini CA, Louw I, Combe B, Beaulieu A, Schulze-Koops H, Dasgupta B, Fu B, Huyck S, Weng HH, Govoni M, Durez P.

Rheumatology (Oxford). 2016 Aug;55(8):1466-76. doi: 10.1093/rheumatology/kew179. Epub 2016 Apr 25.

42.

Differential changes in gene expression in human neutrophils following TNF-α stimulation: Up-regulation of anti-apoptotic proteins and down-regulation of proteins involved in death receptor signaling.

Chiewchengchol D, Wright HL, Thomas HB, Lam CW, Roberts KJ, Hirankarn N, Beresford MW, Moots RJ, Edwards SW.

Immun Inflamm Dis. 2015 Dec 2;4(1):35-44. doi: 10.1002/iid3.90. eCollection 2016 Mar.

43.

Ghost busting--taking the sheet off the ghost.

Moots RJ, Wilson K, Silverman ED.

Z Rheumatol. 2016 Apr;75(3):240-1. doi: 10.1007/s00393-016-0073-7. No abstract available.

PMID:
27038049
44.

Ghostbusting-Taking the sheet off the ghost.

Moots RJ, Wilson K, Silverman ED; International Rheumatology Editors.

Reumatol Clin. 2016 Mar-Apr;12(2):63-4. doi: 10.1016/j.reuma.2016.02.002. English, Spanish. No abstract available.

45.

Inflammatory arthritis in HIV positive patients: A practical guide.

Adizie T, Moots RJ, Hodkinson B, French N, Adebajo AO.

BMC Infect Dis. 2016 Mar 1;16:100. doi: 10.1186/s12879-016-1389-2. Review.

46.

Ghost busting-taking the sheet off the ghost.

Moots RJ, Wilson K, Silverman ED; International Rheumatology Editors.

Rheumatol Int. 2016 Apr;36(4):455-6. doi: 10.1007/s00296-016-3439-x. No abstract available.

PMID:
26910790
47.

Ghost busting--taking the sheet off the ghost.

Moots RJ, Wilson K, Silverman ED; International Rheumatology Editors.

Clin Rheumatol. 2016 Apr;35(4):841-2. doi: 10.1007/s10067-016-3181-5. No abstract available.

PMID:
26895628
48.

Ghost busting, taking the sheet off the ghost.

Moots RJ, Wilson K, Silverman ED.

Mod Rheumatol. 2016;26(3):321-2. No abstract available.

PMID:
26894374
49.

Development of a Rheumatology-specific Patient Concerns Inventory and Its Use in the Rheumatology Outpatient Clinic Setting.

Ahmed AE, Lowe D, Kirton JA, O'Brien MR, Mediana A, Frankland H, Bruce H, Kennedy T, Rogers SN, Moots RJ.

J Rheumatol. 2016 Apr;43(4):779-87. doi: 10.3899/jrheum.150068. Epub 2016 Feb 15.

PMID:
26879357
50.

Ghost Busting, Taking the Sheet Off the Ghost.

Moots RJ, Wilson K, Silverman ED; International Rheumatology Editors.

J Rheumatol. 2016 Apr;43(4):689-90. doi: 10.3899/jrheum.151278. Epub 2016 Feb 15. No abstract available.

PMID:
26879351

Supplemental Content

Loading ...
Support Center